scispace - formally typeset
S

Stanley Nattel

Researcher at Montreal Heart Institute

Publications -  802
Citations -  72437

Stanley Nattel is an academic researcher from Montreal Heart Institute. The author has contributed to research in topics: Atrial fibrillation & Heart failure. The author has an hindex of 132, co-authored 778 publications receiving 65700 citations. Previous affiliations of Stanley Nattel include Mayo Clinic & Brigham and Women's Hospital.

Papers
More filters
Journal ArticleDOI

The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations.

Stanley Nattel, +3 more
- 01 Sep 1994 - 
TL;DR: New approaches currently under study include surgery to prevent AF from sustaining itself, implantable cardioverter devices to maintain sinus rhythm, and modification of AV nodal function by the induction of controlled radiofrequency injury.
Journal ArticleDOI

Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea.

Yu-ki Iwasaki, +6 more
- 01 Sep 2012 - 
TL;DR: Obesity and acute obstructive apnea interacted to promote AF in this model, and forced inspiration-induced acute LA distension related to diastolic dysfunction may be an important component of the arrhythmogenic substrate for AF during OSA episodes in obese patients.
Journal Article

Mechanisms of atrial remodeling and clinical relevance.

Stanley Nattel, +3 more
- 01 Jan 2005 - 
TL;DR: Understanding atrial remodeling has the potential to improve appreciation of the pathophysiology of clinical atrial fibrillation and to allow for the development of useful new therapeutic approaches.
Journal ArticleDOI

Newer developments in the management of atrial fibrillation

Stanley Nattel, +1 more
- 01 Nov 1995 - 
TL;DR: New developments in the management of AF are focused on, including prospects for improved methods to maintain sinus rhythm, newer approaches to rate control, controversies regarding the use of oral anticoagulation, and novel nonpharmacologic therapies.
Journal ArticleDOI

Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure

Masayuki Shimano, +7 more
- 01 Mar 2008 - 
TL;DR: Pioglitazone can attenuate congestive heart failure-induced atrial structural remodeling and AF promotion, with effects similar to those of candesartan, and may be a potential therapeutic target for human AF.